Nordson Q3 2025 slides: 12% revenue growth, portfolio realignment underway

Nordson Corporation (NDSN) reported strong Q3 2025 results, with sales up 12% to $742 million and EBITDA increasing 15% to $239 million, driving a 5.9% premarket stock surge. The company announced a strategic divestiture of select medical contract manufacturing product lines to enhance focus on higher-growth, proprietary medical components, a move anticipated to be accretive to the Medical Fluid Solutions segment's EBITDA margins. This portfolio realignment, combined with robust cash flow generation and reaffirmed long-term targets of 6-8% annual revenue growth and 10-12% adjusted EPS growth through 2029, signals a disciplined approach to value creation.

Analysis

Nordson Corporation (NDSN) demonstrated strong operational and strategic execution in its Q3 2025 results, sparking a 5.9% premarket stock surge. The company reported a 12% year-over-year increase in sales to $742 million, primarily driven by the Atrion acquisition (8%) and favorable currency effects (2%), supplemented by 2% organic growth. Profitability was a key highlight, with EBITDA growing 15% to $239 million and the EBITDA margin expanding 70 basis points to 32% due to higher sales volume and SG&A leverage. A significant strategic development is the announced divestiture of select contract manufacturing lines within its medical business, a move designed to sharpen focus on higher-margin, proprietary medical components and expected to be accretive to the Medical Fluid Solutions segment's EBITDA. This portfolio realignment is supported by robust cash flow generation, with free cash flow at $226 million (a 180% conversion of net income) being deployed towards debt reduction ($109 million), share repurchases ($71 million), and dividends ($44 million), all while maintaining a healthy 2.2x net leverage ratio. While Nordson reaffirmed its full-year 2025 guidance, it noted that sales are tracking slightly below the midpoint of its range, whereas adjusted EPS is tracking slightly above, suggesting stronger-than-anticipated profitability is offsetting a modest top-line lag. The company's long-term financial targets through 2029, calling for 6-8% annual revenue growth and 10-12% adjusted EPS growth, underscore a continued focus on disciplined M&A and operational excellence across its diversified end markets.

Key Decisions for Investors

• Investors should view the combination of strong Q3 profitability, a shareholder-friendly capital allocation policy, and the strategic divestiture as a positive catalyst that reinforces the company's growth narrative.
• It is critical to monitor the execution of the medical segment's restructuring for evidence of the projected margin accretion and to track for an acceleration in the 2% organic growth rate, which currently lags acquisitive growth.
• Given that full-year sales are tracking slightly below the guidance midpoint while EPS is tracking above, investors should assess if the enhanced profitability and strategic actions sufficiently justify the valuation following the recent stock price appreciation.
• The 61-year history of annual dividend increases and significant buyback activity makes NDSN a compelling consideration for Growth at a Reasonable Price (GARP) investors, though they must remain aware of the reliance on M&A for a significant portion of recent top-line expansion.